ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > ADCのPK解析ツール--抗ペイロード抗体

ADC PK 分析用ツールーー抗ペイロード抗体

Tools for ADC PK Analysis——Anti-payload antibodies
製品の特徴
高純度 (>90%)
高い親和性と特異性が検証済み
ADC結合アッセイにより高感度が検証済み
テクニカル サポート
ここをクリックしてデータを表示>>
研究用途
前臨床および臨床における ADC に関する ELISA PK/PD 研究
DAR値の検出
Background
生物学的医薬品の特性評価は、開発から臨床評価まで、医薬品開発プロセス全体にわたる重要なステップです。
抗体薬物複合体 (ADC) は、複雑で多様な構造を持っています。マトリックスの複雑さと生物種も含まれ、DAR と PK/PD 研究は異なる要素に向けて、包括的に評価する必要があります。 ADC の各要素には、特性評価のための異なる基準があります。これには、ELISA や LC-MS などの分析方法の利用が含まれます。
TypeAnalyte DetailTypical Method
Total AntibodyConjugated, partially unconjugated, and fully unconjugated (DAR > 0)Ligand Binding Assay
Conjugated AntibodyAntibody with minimum DAR > 1Ligand Binding Assay
Antibody-conjugated DrugTotal small-molecule drug conjugated to AntibodyAffinity LC-MS / Ligand Binding Assay
Unconjugated DrugSmall molecule drug not conjugated to antibodyLC-MS
Total DrugTotal unconjugated and conjugated DrugLC-MS

ADC 分子の種類と評価のための代表的な分析方法1

Different LBA formats to analyze ADCs in serum

血清 中の ADC を分析するためのさまざまな LBA フォーマット 2

ADC を評価する際の PK 研究を支援するために、ACROBiosystems は、DM-1、DXD、SN38、MMAE などに特異的に結合する、高い親和性を持つ抗ペイロード抗体も提供できます。二次抗体の必要性を排除するために、HRP 結合抗 MMAE 抗体も提供しております。
製品リスト
MoleculeCat. No.Product DescriptionPreorder/Order
最新情報!高品質の抗ペイロード抗体は ACROBiosystems から間もなくリリースします。ご提案やカスタムリクエストがある場合は、こちらをクリックしてご連絡ください.

Assay Data
Case study: PK method development and sample Detection
Immobilized with anti-DXD antibody for quantitative detection of T-Dxd concentration in serum.
Immobilized with anti-DXD antibody for quantitative detection of T-Dxd concentration in serum.

Immobilized Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) at 1 μg/mL, add Trastuzumab deruxtecan in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Immobilized with HER2, and adds Biotinylated anti-DXD antibody as the secondary antibody for quantitative measurement of T-Dxd concentration in serum.
Immobilized with HER2, and adds Biotinylated anti-DXD antibody as the secondary antibody for quantitative measurement of T-Dxd concentration in serum.

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag (Cat. No. DXD-BVM807) at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Immobilized with anti-MMAE antibody for quantitative detection of RC48 concentration in serum.
Immobilized with anti-MMAE antibody for quantitative detection of RC48 concentration in serum.

Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Immobilized with anti-DM1 antibody for quantitative detection of Trastuzumab-DM1 concentration in serum.
Immobilized with anti-DM1 antibody for quantitative detection of Trastuzumab-DM1 concentration in serum.

Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Purity over 90% verified by SEC-MALS
Purity over 90% verified by SEC-MALS

The purity of Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-M684) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.

Purity over 90% verified by SEC-MALS

The purity of Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

High affinity with ADCs verified by ELISA
High affinity with ADCs verified by ELISA

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).

High affinity with ADCs verified by ELISA

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

High affinity with ADCs verified by ELISA

Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).

High affinity with ADCs verified by ELISA

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-PLM684) with a linear range of 0.5-31 ng/mL (Routinely tested).

プロトコル

ADC の免疫原性を評価するための重要な試薬 - 抗イディオタイプ抗体
MoleculeCat. No.Product DescriptionNeutralizing activityApplication
Adalimu*abADB-Y19Anti-Adalimu*ab Antibodies (AY19)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Adalimu*abADB-Y23bAnti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD)Non-Neutralizing AntibodyPK bridging ELISA; Indirect ELISA
Bevacizu*abBEB-Y10Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-Y12Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-Y9Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*abBEB-BY13Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA;Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-Y27Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-Y31Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing)Non-Neutralizing AntibodyADA assay; Indirect ELISA
Cetuxi*abCEB-Y28Anti-Cetuxi*ab Antibodies (AY28)Neutralizing AntibodyADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*abCEB-BY31Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD)Non-Neutralizing AntibodyPK bridging ELISA; Indirect ELISA
Rituxi*abRIB-Y36Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay)Neutralizing AntibodyADA assay;Neutralizing assay; Indirect ELISA
Rituxi*abRIB-Y37Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA;Neutralizing assay;Indirect ELISA
Rituxi*abRIB-Y35cAnti-Rituxi*ab Antibodies (MALS verified)Non-Neutralizing AntibodyADA assay; Indirect ELISA
Trastuzu*abTRB-Y5bAnti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA
Trastuzu*abTRB-Y1bAnti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD)Neutralizing AntibodyPK bridging ELISA; Neutralizing assay; Indirect ELISA

>> クリックして、ADC の開発を加速するコア試薬の詳細をご覧ください。
Antibody-Drug Conjugates (ADCs): the Magic Bullets for Treatment

参考文献

1. Gorovits, B. et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5, 997–1006 (2013).

2. Qin, Q. & Gong, L. Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27, 1–17 (2022).

ACRO Quality

This web search service is supported by Google Inc.

totopphone